European Journal of Cancer
Volume 46, Issue 15 , Pages 2671-2673, October 2010

A phase 2 study of vatalanib in metastatic melanoma patients☆

  • Natalie Cook

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Bristi Basu

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Swethajit Biswas

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Paula Kareclas

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Colette Mann

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Cheryl Palmer

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Anne Thomas

      Affiliations

    • Dept. of Cancer Studies and Molecular Medicine, University of Leicester, University Hospitals of Leicester NHS Trust (Leicester Royal Infirmary), Leicester, UK
    • ,
  • Steve Nicholson

      Affiliations

    • Dept. of Cancer Studies and Molecular Medicine, University of Leicester, University Hospitals of Leicester NHS Trust (Leicester Royal Infirmary), Leicester, UK
    • ,
  • Bruno Morgan

      Affiliations

    • Dept. of Cancer Studies and Molecular Medicine, University of Leicester, University Hospitals of Leicester NHS Trust (Leicester Royal Infirmary), Leicester, UK
    • ,
  • David Lomas

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Bhawna Sirohi

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • ,
  • Adrian P. Mander

      Affiliations

    • MRC Biostatistics Unit Hub in Trials Methodology Research, Cambridge, UK
    • ,
  • Mark Middleton

      Affiliations

    • University of Oxford, Department of Medical Oncology, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK
    • ,
  • Pippa G. Corrie

      Affiliations

    • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital), Cambridge, UK
    • Corresponding Author InformationCorresponding author: Address: Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK. Tel.: +44 1223 274401; fax: +44 1223.

Received 25 June 2010; received in revised form 13 July 2010; accepted 14 July 2010. published online 27 August 2010.

Abstract 

Background

A phase 2 study of vatalanib (PTK787/ZK222584) an oral tyrosine kinase inhibitor of VEGFR 1, 2 and 3 was undertaken in patients with metastatic melanoma.

Methods

Adults with pathologically confirmed metastatic melanoma, WHO Performance status 0–2, and adequate haematological, hepatic and renal function, were treated with vatalanib until disease progression. The trial used Fleming’s single stage design.

Results

Tumour control rate (CR+PR+SD) was 35% at 16weeks, with objective response seen in only 1 patient. Median progression-free survival was 1.8months (95% CI 1.8–3.7months) and median overall survival was 6.5months (95% CI 3.9–10.2months).

Conclusion

Vatalanib stabilised disease in a proportion of patients, although overall survival was disappointing.

Keywords: NGR-hTNF, Vascular targeting agent, Colorectal cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Research Support: This study was sponsored by Cambridge University Hospitals NHS Foundation Trust, adopted by the UK National Cancer Research Institute (NCRI), supported by grants from Bayer Schering Pharma and Addenbrooke’s Charitable Trust. M.R.M. is supported by the NIHR Biomedical Research Centre, Oxford.

PII: S0959-8049(10)00692-1

doi:10.1016/j.ejca.2010.07.014

European Journal of Cancer
Volume 46, Issue 15 , Pages 2671-2673, October 2010

Article Tools